Clinical trials
3 active studies led by RHEACELL GmbH & Co. KG, of 11 in all
Source: ClinicalTrials.gov, Studies with RHEACELL GmbH & Co. KG (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
- 0Reports naming them
- 1Markets in public records
- 0Regions & countries
- 3Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by RHEACELL GmbH & Co. KG or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public data on RHEACELL GmbH & Co. KG
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
See them on ClinicalTrials.gov (opens in a new tab)
Trials over time
Studies RHEACELL GmbH & Co. KG leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with RHEACELL GmbH & Co. KG or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets where public records show them
Markets we cover where free public records show RHEACELL GmbH & Co. KG: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Healthcare Topics
The topics of the markets RHEACELL GmbH & Co. KG is in.
From our blog
Stories on the topics RHEACELL GmbH & Co. KG works in.
Patient Support Programmes: Helping Patients Stay on Treatment
WHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient…
Read
Biologic Safety Testing: The Quiet Backbone of Drug Making
Every vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches…
Read
Cell-Based Immunotherapy: Promise and Price
The first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
Read